CN115054611B - Medicine for treating infantile pneumonia and application thereof - Google Patents
Medicine for treating infantile pneumonia and application thereof Download PDFInfo
- Publication number
- CN115054611B CN115054611B CN202210848707.2A CN202210848707A CN115054611B CN 115054611 B CN115054611 B CN 115054611B CN 202210848707 A CN202210848707 A CN 202210848707A CN 115054611 B CN115054611 B CN 115054611B
- Authority
- CN
- China
- Prior art keywords
- pneumonia
- medicine
- luteolin
- group
- infantile pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims abstract description 21
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 18
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000009498 luteolin Nutrition 0.000 claims abstract description 18
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960004626 umifenovir Drugs 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 210000004072 lung Anatomy 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 208000032023 Signs and Symptoms Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 206010035737 Pneumonia viral Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000009421 viral pneumonia Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 240000005001 Paeonia suffruticosa Species 0.000 description 2
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100113067 Rattus norvegicus Cfi gene Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000002911 sialidase inhibitor Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine for treating infantile pneumonia and application thereof, wherein the active ingredient of the medicine is a combination of arbidol or pharmaceutically acceptable salt thereof and luteolin. According to the invention, the arbidol or the pharmaceutically acceptable salt thereof and the luteolin are combined according to a specific proportion, and the addition of the luteolin is beneficial to improving the treatment effect of the arbidol on treating the infantile pneumonia (especially viral infantile pneumonia).
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating infantile pneumonia and application thereof.
Background
The infantile pneumonia (pneumonia) is lung inflammation caused by pathogens (such as bacteria, viruses and the like) and other factors (such as inhalation of amniotic fluid, meconium and the like), is a respiratory disease most common in the childhood period, and mainly shows symptoms of fever, cough, shortness of breath, dyspnea, lung wetting and the like.
Pneumonia is a common disease in infants and is the first cause of death in children under 5 years old, and the pneumonia is well developed in winter and spring. According to the world health organization data, the death number of children under 5 years old caused by pneumonia in 2016 is up to 92 ten thousand, 98% of the deaths occur in developing countries, and the pneumonia is also a main cause of death of children under 5 years old in China.
Viral pneumonia is the most common type of infant pneumonia. Respiratory syncytial virus is the first viral pathogen causing childhood pneumonia, followed by parainfluenza virus (type I, type II, type III) and influenza virus (type a, type B). The drug treatment of common viral pneumonia mainly comprises: for influenza virus, neuraminidase inhibitors can be applied, and are effective on both influenza A virus and influenza B virus. Patients with severe or severe influenza high risk factors should be given anti-influenza virus therapy as early as possible within 48 hours without waiting for virus detection results. Antiviral treatment is still helpful to the infant for severe patients over 48 hours.
Abidol is an antiviral drug, is developed by the research center of Soviet Union pharmaceutical chemistry, and has the main indications of influenza caused by influenza A and B viruses and antiviral activity on other respiratory tract virus infections. Abidol is suitable for the prevention and treatment of influenza A, influenza B, acute viral respiratory infections, severe acute respiratory syndromes, including concurrent bronchitis and pneumonia, in adults and children. Abidol hydrochloride is used in early stage after influenza is developed, so that the duration of the disease can be obviously shortened, the severity of symptoms can be reduced, the cough, headache, fever, chill, sweating, sore throat, muscle soreness, fatigue and other symptoms of influenza patients can be improved, and the oral liquid has good safety and is suitable for clinical popularization and use. The usage amount is 100 mg/granule, which is orally taken, 2 granules for children over 13 years old and adults, 1 granule for children 6-12 years old and 50mg for children 2-6 years old. Treatment: 3 times a day, taking 3-5 d. Prevention of: the influenza is taken 1 time every 3 days in the running period and continuously taken for 3 weeks; the high risk group who is in contact with the patient takes the medicine 1 time a day for 2 weeks. However, the use of arbidol for the treatment of viral pediatric pneumonia has not been reported in the literature, probably because of the limited targeting and therapeutic efficacy of arbidol for viral pediatric pneumonia. Therefore, how to obtain a drug that can be effectively used for treating infantile pneumonia is still a technical problem to be solved by those skilled in the art.
Disclosure of Invention
Based on the background technology, the technical problem to be solved by the invention is to provide a pharmaceutical composition for treating infantile pneumonia and application thereof. In order to achieve the aim of the invention, the following technical scheme is adopted:
in one aspect, the invention relates to a medicament for treating infantile pneumonia, wherein the active ingredient of the medicament is a combination of arbidol or pharmaceutically acceptable salt thereof and luteolin. Although luteolin alone has little effect on the treatment of pediatric pneumonia (particularly viral pediatric pneumonia), it helps to improve the efficacy of arbidol in the treatment of pediatric pneumonia when combined with arbidol.
In a preferred embodiment of the present invention, the weight ratio of the arbidol or a pharmaceutically acceptable salt thereof and luteolin is 4:1-3; preferably 4:1.5-2.5; particularly preferably 4:1.8-2.2. The invention is beneficial to further improving the effect of treating the infantile pneumonia by controlling the weight ratio of the arbidol to the luteolin in the preferred range of the invention.
In a preferred embodiment of the invention, the medicament contains or does not contain other active ingredients.
In another preferred embodiment of the invention, the medicament further comprises pharmaceutically acceptable excipients.
In a preferred embodiment of the present invention, the drug is an oral formulation including, but not limited to, syrups, tablets, capsules, etc.; preferably, the oral formulation is a syrup. The pharmaceutical composition is prepared into syrup, so that the syrup is more favorable for children to accept, and the compliance of patients can be improved.
The invention also relates to the application of the medicine, and the medicine is used for preparing medicines for treating infantile pneumonia.
In a preferred embodiment of the invention, the medicament is for the treatment of viral pediatric pneumonia.
Advantageous effects
According to the invention, the arbidol or the pharmaceutically acceptable salt thereof and the luteolin are combined according to a specific proportion, and the addition of the luteolin is beneficial to improving the treatment effect of the arbidol on treating the infantile pneumonia (especially viral infantile pneumonia).
Detailed Description
In order to further understand the present invention, a technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Unless otherwise specified, all reagents involved in the examples of the present invention are commercially available products and are commercially available.
Example 1: animal experiments.
1 Material
1.1 laboratory animals and groups
60 adult Wistar rats with a body mass of 180-230g are provided by the laboratory animal center of the medical college of Paeonia suffruticosa. Randomly divided into blank group, model group, abidol and luteolin group 1, abidol and luteolin group 2, abidol and luteolin group 3.
1.2 pharmaceutical products and reagents
Abidol and luteolin were purchased from reagent company.
2 Experimental methods
2.1 grouping and administration of animals
After the experimental rats were adaptively bred for 3 days, 60 experimental rats were randomly divided into a blank group, a model group, an Abidol group (4 mg/kg/d), an Abidol (4 mg/kg/d) and luteolin (1 mg/kg/d) combination group 1, an Abidol (4 mg/kg/d) and luteolin (2 mg/kg/d) combination group 2, an Abidol (4 mg/kg/d) and luteolin (3 mg/kg/d) combination group 3, 10 animals each. Except for the blank groups, each group of animals was subcutaneously injected with cyclophosphamide at 100mg/kg body weight. On day 4 after dosing, rats were lightly anesthetized with diethyl ether, with drops of influenza a H1N1 virus, each 60 μl, except for the blank group. Weighing the weight of the rat on the 20 th day after infection, and freezing and preserving the dead rat if the rat dies in advance; whole lung was dissected and weighed, and lung index inhibition were calculated.
2.2 statistical treatment
Lung index = wet lung weight/body weight
Pulmonary index inhibition = (model group lung weight-treatment group lung weight)/(model group lung weight-blank group lung weight) ×100%
The death of the experimental rats within 20 days after infection was observed, and mortality, mortality protection, average survival days, and life extension were calculated.
Life extension = (treatment group survival days-model group survival days)/model group survival days x 100%.
The statistical software SPSS 25.0 was used for t-test or analysis of variance, with P <0.05 being statistically significant, and the results are shown in table 1.
TABLE 1 animal model test results
Experimental results show that the lung index is extremely significantly increased (P < 0.01) in the model group compared to the blank group; the lung index was very significantly reduced (P < 0.01) for each treatment group compared to the model group. The Abidol and luteolin combined group 1-3 has significant difference (P < 0.01) from the model group, and particularly the Abidol and luteolin combined group 2 can obviously reduce the lung index of a rat with pneumonia and can also obviously prolong the life of the infected rat.
Example 2: clinical pharmacodynamic experiments
1 data and method
1.1 general data: the method comprises the steps of selecting a total of 40 cases of viral pneumonia infants treated by pediatric inpatients of a second hospital attached to the Paeonia suffruticosa medical college from 1 month of 2022 to 6 months of 2022 as study objects, randomly dividing the infants into a treatment group and a control group according to a random digital table method, wherein the total number of the infants is 40. The average age, course and body weight of the two groups of infants were compared, and the differences were not statistically significant (P > 0.05) and were comparable, as shown in table 2.
Table 2 patient general data comparison
1.2 treatment method:
control group: erythromycin 20 mg/(kg.d) was used for 2 intravenous instillations;
treatment group: the medicine composition (containing Abidol 4mg/mL, luteolin 2mg/mL, sucrose 0.1 g/mL) is added for 15-30 mL/time based on the control group treatment, and is orally taken for 3 times a day.
1.3 observations index:
observing the symptoms (cough and fever) of two groups of traditional Chinese medicine before and after treatment, the lung function changes, the clinical curative effect and the like.
1.4 clinical efficacy decision criteria:
formulation of "Chinese medical condition diagnosis efficacy Standard" is referred to:
and (3) healing: the symptoms disappear or basically disappear, the integral of symptoms is reduced by more than or equal to 95%, and the X-ray review of the lung is normal;
the effect is shown: the symptoms and signs are obviously improved, the integral of symptoms and signs is reduced by more than 70%, and the focus of X-ray examination of the lung is not completely absorbed yet;
the method is effective: the symptoms and signs are improved, the integral of symptoms and signs is reduced by between 70 and 30 percent, and the focus of X-ray examination of the lung is still partially absorbed;
invalidation: the symptoms and signs are not obviously improved or even aggravated, the integral of symptoms and signs is reduced by <30%, and the focus of X-ray examination of the lung is unabsorbed or even increased.
2 results
2.1 two groups of symptoms of cough and fever before and after treatment are compared in integral form as shown in Table 3.
TABLE 3 integral comparison of cough symptoms and fever symptoms before and after treatment (x+ -s) for patients
As can be seen from table 3, the cough symptoms and fever symptoms integral of the two groups of infants after treatment are significantly reduced compared with those before treatment, and the difference is statistically significant (P < 0.05), and the cough symptoms and fever symptoms integral reduction value of the infants after treatment is higher than that of the control group, and the difference is statistically significant (P < 0.05).
2.2 comparison of the two groups of comprehensive curative effects is shown in Table 4.
Table 4 comparison of patient's overall treatment effects
| Group of | n | Healing of the wound | Has obvious effect | Effective and effective | Invalidation of | Rate of more visible (%) | Total effective rate (%) |
| Treatment group | 20 | 12 | 5 | 3 | 1 | 85 | 95 |
| Control group | 20 | 8 | 4 | 3 | 5 | 60 | 75 |
Compared with the total effective rate of the two groups of children, the treatment group has significantly higher curative rate (83%) and total effective rate (97%) than the control group, and the difference has statistical significance (P < 0.05).
The foregoing describes preferred embodiments of the present invention, but is not intended to limit the invention thereto. Modifications and variations to the embodiments disclosed herein may be made by those skilled in the art without departing from the scope and spirit of the invention.
Claims (4)
1. An application of a medicine for treating infantile pneumonia in preparing the medicine for treating infantile pneumonia, wherein the active ingredients of the medicine for treating infantile pneumonia are the combination of arbidol or pharmaceutically acceptable salt thereof and luteolin; the weight ratio of the arbidol or the pharmaceutically acceptable salt thereof to the luteolin is 4:1.8-2.2; the infantile pneumonia is viral infantile pneumonia.
2. The use according to claim 1, wherein the medicament for treating pediatric pneumonia further comprises a pharmaceutically acceptable adjuvant.
3. The use according to claim 2, wherein the medicament for treating pediatric pneumonia is an oral formulation selected from the group consisting of syrups, tablets, capsules.
4. The use according to claim 3, wherein the oral formulation is a syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210848707.2A CN115054611B (en) | 2022-07-19 | 2022-07-19 | Medicine for treating infantile pneumonia and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210848707.2A CN115054611B (en) | 2022-07-19 | 2022-07-19 | Medicine for treating infantile pneumonia and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115054611A CN115054611A (en) | 2022-09-16 |
| CN115054611B true CN115054611B (en) | 2023-12-29 |
Family
ID=83205575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210848707.2A Active CN115054611B (en) | 2022-07-19 | 2022-07-19 | Medicine for treating infantile pneumonia and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115054611B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552321A (en) * | 2003-06-05 | 2004-12-08 | 中奇制药技术（石家庄）有限公司 | Use of Abidol in preparing medicines for treating and preventing SARS virus |
| CN111904959A (en) * | 2020-08-21 | 2020-11-10 | 牡丹江医学院 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
| CN112546046A (en) * | 2020-12-15 | 2021-03-26 | 天津济坤医药科技有限公司 | Application of arbidol hydrochloride in preparation of medicine for treating pulmonary fibrosis diseases |
| CN114504571A (en) * | 2022-04-11 | 2022-05-17 | 黑龙江中医药大学 | Pharmaceutical composition for treating infantile pneumonia and application thereof |
-
2022
- 2022-07-19 CN CN202210848707.2A patent/CN115054611B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1552321A (en) * | 2003-06-05 | 2004-12-08 | 中奇制药技术（石家庄）有限公司 | Use of Abidol in preparing medicines for treating and preventing SARS virus |
| CN111904959A (en) * | 2020-08-21 | 2020-11-10 | 牡丹江医学院 | Application of alpha-L-fucosidase inhibitor in preparation of medicine for treating infantile pneumonia |
| CN112546046A (en) * | 2020-12-15 | 2021-03-26 | 天津济坤医药科技有限公司 | Application of arbidol hydrochloride in preparation of medicine for treating pulmonary fibrosis diseases |
| CN114504571A (en) * | 2022-04-11 | 2022-05-17 | 黑龙江中医药大学 | Pharmaceutical composition for treating infantile pneumonia and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 盐酸阿比朵尔胶囊抗甲型Ｈ1Ｎ1流感病毒的体外实验研究;刘强等;中国药学杂志;第46卷(第02期);第108-112页 * |
| 黄芩苷和木犀草苷在体外对流感病毒H1N1感染A549细胞中NF-κB信号通路的调控作用;刘晓婷等;中华中医药杂志;第31卷(第05期);第1937-1941页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115054611A (en) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhao et al. | Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening | |
| EP3854398A1 (en) | Use of favipiravir in the treatment of coronavirus infection | |
| KR101706624B1 (en) | Agent for the prophylaxis and treatment of highly pathogenic infectious diseases | |
| KR20120002981A (en) | Pharmaceutical formulations and methods for treating respiratory tract infections | |
| WO2023165566A1 (en) | Drug for treating and preventing related diseases caused by viral infections, and use thereof | |
| Phillpotts et al. | Intranasal Lymphoblastoid Interferon (" Well fer on") Prophylaxis Against Rhinovirus and Influenza Virus in Volunteers | |
| CN111214550A (en) | New application of medicine in treating or preventing novel coronavirus pneumonia 2019-nCoV | |
| WO2022199049A1 (en) | Use of ulinastatin in preparation of drug for treating novel coronavirus pneumonia | |
| WO2022199050A1 (en) | Use of ulinastatin in preparation of medication for preventing and treating severe covid-19 | |
| CN115054611B (en) | Medicine for treating infantile pneumonia and application thereof | |
| Li et al. | A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China | |
| EP3393517B1 (en) | Acetylsalicylic acid for use in the treatment of moderate to severe influenza | |
| Higgins et al. | Failure to demonstrate synergy between interferon-α and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers | |
| JP2010528053A (en) | Substances and methods for treating influenza infections | |
| CN102716128A (en) | Pharmaceutical composition for treating asthma | |
| Togo et al. | Antiviral effect of 3, 4-dihydro-1-isoquinolineacetamide hydrochloride in experimental human rhinovirus infection | |
| CN1742998A (en) | Use of interferon alpha-1b for preparing medicine for preventing and treating upper respiratory tract inflammation | |
| Wu | Clinical effect of oseltamivir phosphate in the treatment of influenza | |
| CN117462633A (en) | Application of Jingyin exterior-securing prescription in treating influenza and influenza secondary bacterial infection diseases | |
| CN114917285B (en) | Application of polysaccharide compound in medicine for preventing and treating respiratory tract virus infection | |
| CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
| WO2022250578A1 (en) | Use of 2-(imidazol-4-yl)-ethanamide 1,5-pentanedioic acid to treat covid-19 | |
| CN114469913B (en) | Use of Tilorone for preventing/treating African swine fever virus infection | |
| RU2772701C1 (en) | Methods for treating infectious diseases caused by coronavirus | |
| US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |